RxDoctor Payments Data

David Batt, MD

Rheumatology · Indianapolis, INNPI 1972547529

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $513,138 of the $577,110 with a category attached, or 88.9%. It is spread thinly across 17 manufacturers, the largest accounting for just 21.9%. Reporting peaked in 2019 at $156,390 and has fallen 54.7% since, to $70,786 in 2025. Among rheumatology clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$577,110in general payments, 2019–2025

Across 698 payments — averaging $826.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$126K
  • Amgen$100K
  • Mallinckrodt Enterprises LLC$98K
  • Mallinckrodt Hospital Products Inc.$94K
  • Boehringer Ingelheim$57K
  • AstraZeneca$39K
  • plus $63K from 11 others

What the payments were for

  • Consulting fees$18,2753%
  • Speaking & faculty fees$513,13889%
  • Travel & lodging$27,7505%
  • Food & beverage$17,8333%
  • Education$740%
  • Gifts$410%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$577,110 in reported general payments places this provider in the 95th percentile of 106 rheumatology providers in Indiana.

See all rheumatology providers in Indiana

Medicare billing

Part B allowed, 2024
$17,266
Medicare patients
78
Services billed
183

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate13$168,955
Humira(Cf) PenAdalimumab16$106,008
KevzaraSarilumab11$47,007
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen177$4,539
Celecoxib23$4,441
Hydroxychloroquine Sulfate129$4,223
Acetaminophen-CodeineAcetaminophen With Codeine100$4,035
MethotrexateMethotrexate Sodium131$3,874
Diclofenac Sodium85$3,376
Leflunomide27$2,581
Prednisone251$2,171
Mycophenolate Mofetil30$2,036
Azathioprine56$1,576
Tramadol Hcl138$1,346
Sulfasalazine DrSulfasalazine11$1,122

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev$56,657$168,95513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 106 rheumatology providers in Indiana.

Other rheumatology in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →